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Abstract
The complement system is the main arm of the vertebrate innate immune system against pathogen infection. For the
protozoan Trypanosoma cruzi, the causative agent of Chagas disease, subverting the complement system and invading the
host cells is crucial to succeed in infection. However, little attention has focused on whether the complement system can
effectively control T. cruzi infection. To address this question, we decided to analyse: 1) which complement pathways are
activated by T. cruzi using strains isolated from different hosts, 2) the capacity of these strains to resist the complement-
mediated killing at nearly physiological conditions, and 3) whether the complement system could limit or control T. cruzi
invasion of eukaryotic cells. The complement activating molecules C1q, C3, mannan-binding lectin and ficolins bound to all
strains analysed; however, C3b and C4b deposition assays revealed that T. cruzi activates mainly the lectin and alternative
complement pathways in non-immune human serum. Strikingly, we detected that metacyclic trypomastigotes of some T.
cruzi strains were highly susceptible to complement-mediated killing in non-immune serum, while other strains were
resistant. Furthermore, the rate of parasite invasion in eukaryotic cells was decreased by non-immune serum. Altogether,
these results establish that the complement system recognizes T. cruzi metacyclic trypomastigotes, resulting in killing of
susceptible strains. The complement system, therefore, acts as a physiological barrier which resistant strains have to evade
for successful host infection.
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Introduction
Chagas disease is an illness that affects 18 million people in
Latin America [1]. It is caused by the protozoan parasite
Trypanosoma cruzi and is mainly transmitted by triatomine insects,
although congenital, oral and blood transfusion transmission has
also been reported [2,3,4,5,6,7]. In the insect vector, T. cruzi are
present as replicative non-infective epimastigotes, which differen-
tiate to non-replicative infective metacyclic trypomastigotes.
During the infection, metacyclic trypomastigotes have to evade
the host innate immune system and infect cells to progress in the
infection. Parasites that succeed in infecting host cells differentiate
to amastigotes, an intracellular replicative stage, which after
several divisions differentiate to bloodstream trypomastigotes that
disrupt cells, infecting new cells, or are taken by insect vectors
restarting the life cycle [8].
The first barrier against a microbe’s infection of vertebrates is
the innate immune system, encompassing the complement system
and phagocytic and natural killer cells. The complement system is
one of the most effective innate mechanisms of host defense
against a pathogen infection. It is composed of several proteins
activated in a cascade that culminate with membrane attack
complex formation on the pathogen surface, causing killing by cell
lysis [9]. The complement system can be activated by three
pathways: classical, activated when IgG or IgM bind to the
pathogen surface and associate with the C1 complex (C1qr2s2),
which cleaves C2 and C4 to form C3 convertase (C4b2a); lectin,
activated when mannan-binding lectins (MBLs), L-ficolins or H-
ficolins bind to the pathogen surface and associate with MBL-
associated serine protease-2 (MASP2) to cleave C2 and C4,
generating C3 convertase (as in the classical pathway); and
alternative, activated when C3b binds to the pathogen surface and
associates with factor B to form C3 convertase (C3bBb) [9].
During T. cruzi infection, it is estimated that 10
4 to 10
5
metacyclic trypomastigotes are released by the insect vector
[10,11], which rapidly penetrate the host skin [12,13]. In the
absence of specific antibodies, the complement alternative and
lectin pathways are responsible for triggering the complement
system against the pathogens in the bloodstream. Metacyclic
trypomastigotes, derived from triatomine vectors or axenic
cultures, were shown to be killed by the complement with non-
immune sera [14,15]. Also, C3b was detected on the surface of
metacyclic trypomastigotes, although less efficiently than on
epimastigotes [16,17]. Gp72 was identified as the main C3b
acceptor in epimastigotes, but it is a poor C3b acceptor in
metacyclic trypomastigotes [16]. The reduced activation of the
alternative pathway by metacyclic trypomastigotes compared to
epimastigotes is thought to be due to the failure of factor B to
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rapid binding of MBLs, L-ficolins and H-ficolins on the surface of
metacyclic trypomastigotes has been shown, providing evidence
that the lectin pathway is activated in non-immune serum by T.
cruzi [19]. Furthermore, bloodstream trypomastigotes sensitized
with antibodies from acutely infected animals were killed by the
complement system in human serum [20,21], and anti-a-
galactosyl antibodies recognizing O-linked oligosaccharides on
T. cruzi mucin-like GPI-anchored proteins were identified in
chronic phase Chagas disease patients [22,23]. Altogether, these
data support the idea that the complement system can recognize
and kill the infectious stages of T. cruzi.
The expression of complement system inhibitors, such as
complement C2 receptor inhibitor trispanning, complement
regulatory protein, calreticulin and decay accelerating factor, has
been demonstrated in T. cruzi; these molecules help T. cruzi to
avoid complement killing [24,25,26,27]. However, the levels of
expression and functionality of these molecules could be different
among T. cruzi strains, since resistance to complement killing has
been demonstrated to vary among them [20,24]. Despite the
mechanisms of resistance to the complement system, the
differences of T. cruzi strains and the high parasite load required
for infection suggest that not all metacyclic trypomastigotes
succeed in infecting the host [12,28,29,30,31].
Aiming to understand how T. cruzi metacyclic trypomastigotes
interact with the human complement system, we analysed the
effect of the complement system on the lysis and eukaryotic cell
invasion by several T. cruzi strains. Firstly, through C3b and C4b
deposition assays we found that T. cruzi mainly activate the lectin
and alternative pathways in non-immune serum. In vitro assays
revealed that metacyclic trypomastigotes of several strains of T.
cruzi differ in their capacity to resist the complement system, and
some of them were killed after incubation in non-immune human
serum. Moreover, the rate of T. cruzi invasion of eukaryotic cells
was significantly reduced in the presence of non-immune human
serum, showing that the complement system acts as a physiological
barrier for T. cruzi infection and strains resistant to complement
system have a higher chance to succeed in the infection.
Results
1- Complement activating factors bind to the surface of
T. cruzi strains
To determine whether different strains of T. cruzi would activate
the complement system in human serum, the binding of
complement activating factors to these strains was analyzed. T.
cruzi epimastigotes were used because they are sensitive to
complement killing; therefore, they activate the complement
system. Strains from congenitally transmitted Chagas disease
patients, in addition to recently isolated strains from primate,
opossum and rodent were studied (Table 1). The strains Y, Silvio
X10/6, and CL Brener are used by several laboratories and were
also included in some of the experiments.
Binding of C1q, involved in classical pathway activation; MBLs,
L-ficolins and H-ficolins, for the lectin pathway, and C3 for the
alternative pathway were analyzed by ELISA. All these molecules
were detected bound to the parasites after incubation with non-
immune human serum (Figure 1A to E). Although a slight
difference in the binding was detected among the strains, the
results show that all T. cruzi strains are recognized by the
complement activating molecules.
2- T. cruzi strains activate mainly the lectin and
alternative complement pathways
To determine the contribution of each pathway to the
complement activation by T. cruzi strains, kinetic assays were
performed to detect C3b and C4b deposition on the parasite
surface. To analyze the classical and lectin pathway contribution,
C4b deposition assays were performed with normal human serum
(classical and lectin pathway activation), with serum depleted of
MBLs and L-ficolins (mainly classical pathway activation) and with
serum depleted of C1q (lectin pathway activation). C4b deposition
in normal human serum was rapid and similar between all strains,
reaching 50% (absorbance =1.0) in less than 5 minutes
(Figure 2A). However, C4b deposition in MBLs/ficolins-depleted
serum was slower than in normal human serum (Figure 2B). C4b
Table 1. Trypanosoma cruzi strains, hosts and biome.
Phylogenetic group/Isolate Host Biome
TCI 8612 Rattus rattus (rodent) Piauı ´/Brazil
TCI 8628 Rattus rattus (rodent) Jaguaruana, Ceara ´/Brazil
TCI Gamba ´ 05 Didelphis aurita (opossum) Poc ¸o das Antas Reserve, Rio de Janeiro/Brazil
TCII 750 Leontopithecus rosalia (primate) Poc ¸o das Antas Reserve, Rio de Janeiro/Brazil
TCII 812 Leontopithecus rosalia (primate) Poc ¸o das Antas Reserve, Rio de Janeiro/Brazil
TCII 840 Leontopithecus rosalia (primate) Poc ¸o das Antas Reserve, Rio de Janeiro/Brazil
TCII 860 Leontopithecus rosalia (primate) Poc ¸o das Antas Reserve, Rio de Janeiro/Brazil
TCII R4 Triatomae brasilienses (triatominae) Joa ˜o Costa, Piauı ´/Brazil
TCII MLCD88 Leontopithecus chrysomelas (primate) REBIO-Una, Bahia/Brazil
TCII M3 Didelphis albiventris (opossum) White scrub, Piauı ´/Brazil
CL Brener Triatoma infestans (triatominae) Rio Grande do Sul/Brazil
Silvio X10/6 human acute infection Brazil
Tapia Human (newborn child) Molinos, Salta, Argentina
Gareca Human (14 months child) Anta/Argentina
Mendez Human (newborn child) Campo Quijano, Salta/Argentina
Y human acute infection Sa ˜o Paulo/Brazil
doi:10.1371/journal.pone.0009721.t001
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strains. Between 2 to 4 times less deposited C4b was detected in
assays with MBLs/ficolins-depleted serum than with normal
human serum, even after 1 hour of incubation. To examine the
ability of the lectin pathway to recognize T. cruzi and activate the
complement, the C4b deposition was performed in serum depleted
of C1q. The velocity of C4b deposition in this serum was slightly
slower than in normal human serum, but higher than in serum
depleted of MBLs/ficolins (Figure 2C). Substantial depletion of
MBLs/L-ficolins and C1q from sera was confirmed by ELISA
(Figure S1). These results indicate that T. cruzi activate both
classical and lectin pathways; although, as observed before [19],
the lectin pathway seems to be more effective than the classical
pathway in recognizing T. cruzi in non-immune serum. To verify if
these strains activate the alternative pathway, C3b deposition was
analyzed in serum treated with EGTA to chelate Ca
2+.
Importantly, the classical and lectin pathways are Ca
2+- and
Mg
2+-dependent, whereas the alternative pathway is only Mg
2+-
dependent [9]. C3b deposition increased gradually through time
for all strains (Figure 2D). It is noteworthy that strains 8612, Y and
Gamba 05 activated the alternative pathway less than the other
strains analyzed. Together, these results indicate that upon contact
with human serum, T. cruzi strains activate mainly the lectin and
alternative pathways of the complement system.
Figure 1. Complement activating factors bind to T. cruzi surface. A) ELISA for detection of C1q bound to T. cruzi epimastigotes of several
strains. Parasites adsorbed in ELISA plates were incubated with 5% NHS for 1 h at 37uC. Anti-C1q antiserum was used for detection and reactions
were developed with ABTS-peroxidase solution measured at 405 nm. B) Detection of C3b bound to T. cruzi. C) Detection of MBL bound to T. cruzi.D )
Detection of L-ficolins bound to T. cruzi. E) Detection of H-ficolins bound to T. cruzi. Experiments in B, D and E were performed as in A, except that for
detection were used antiserum against C3, L-ficolins and H-ficolins, respectively. Experiments in C were performed as in A, except that 20% NHS and
anti-MBL antiserum were used.
doi:10.1371/journal.pone.0009721.g001
Figure 2. T. cruzi activate mainly the lectin and alternative complement pathways. A) C4b deposition on T. cruzi epimastigotes of several
strains. Parasites adsorbed in ELISA plates were incubated in 5% NHS from 5 to 60 minutes at 37uC, followed by anti-C4 antiserum incubation.
Reactions were developed with ABTS-peroxidase solution measured at 405 nm. B) C4b deposition in epimastigotes of T. cruzi. Experiments were
performed as in A, except that MBLs/L-ficolins-depleted sera were used. C) C4b deposition in epimastigotes of T. cruzi. Experiments were performed
as in A, except that C1q-depleted sera were used. D) C3b deposition in T. cruzi epimastigotes. Experiments were performed as in A; except that sera
treated with 10 mM EGTA and 7 mM MgCl2 were used. Detection was made with anti-C3 antiserum.
doi:10.1371/journal.pone.0009721.g002
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complement system
We have seen previously that the majority of epimastigotes of T.
cruzi strains are susceptible to complement killing in normal
human serum at nearly physiological conditions (50% of serum at
37uC) after incubations ranging from 5 to 30 minutes (not shown).
We decided to analyze whether the metacyclic trypomastigotes of
T. cruzi strains would be resistant to complement killing. Strikingly,
some T. cruzi strains were killed by human complement at nearly
physiological serum concentration, 50% (Figure 3 A and B).
Parasites from the strains Y, R4 and 8628 were completely killed
between 30 to 60 minutes of incubation, whereas the survival rate
of the strains Silvio X10/6, 840, 750, M3 and 812 were no more
than 30% after a 60 minute incubation. The survival rate of the
strains CL Brener, 860 and 8612 was about 50%; and higher
survivals were detected for strains MLCD88 and Gamba 05, about
75%. We also did not find any correlation between the
complement killing susceptibility of the strains and their respective
phylogenetic groups. It is noteworthy that the purity of metacyclic
trypomastigotes used in these assays was always above 95%, as
confirmed by morphological parameters, and they also expressed
the antigen-specific gp82, detected by Western blotting (exempli-
fied in Figure S2). T. cruzi is refractory to the African trypanosome
lytic factor apolipoprotein-I [32,33,34], excluding the possibility
that this factor mediates the lysis. Furthermore, inhibition of the
complement cascade by chelating the Ca
2+ and Mg
2+ from the
serum with EDTA, treatment of the serum with protease inhibitors
or the use of a complement consumed serum failed to lyse T. cruzi
metacyclic trypomastigotes (Figure S3). To obtain further evidence
that metacyclic trypomastigotes are killed by activation of the
complement system, we decided to compare the deposition of C3b
and C4b between epimastigotes and metacyclic trypomastigotes.
There was a higher deposition of C3b and C4b on epimastigotes
than on metacyclic trypomastigotes at 10 minutes incubation with
non-immune serum (Figure 3C and D). However, by 30 minutes
no significant difference for C4b deposition on epimastigotes and
metacyclic trypomastigotes was detected (Figure 3D), confirming
that metacyclic trypomastigotes activate the complement system.
Using a live/dead cells fluorescence-based assay we confirmed
that metacyclic trypomastigotes were being killed after human
serum incubation. For this assay, metacyclic trypomastigotes of the
strain 812 were incubated with or without non-immune human
serum at concentration of 50% for 30 minutes at 37uC, followed
by labeling with calcein-AM (green, to detect live cells) and
ethidium homodimer-1 (red, for dead cells). Serum incubation
resulted in almost complete parasite killing (red), while non-treated
parasites were alive (green) and motile. There were few parasites
survivors after serum treatment, as can be observed in Figure 3E
(arrows). Together, these results show that T. cruzi metacyclic
trypomastigotes activate the complement system, and there are
strains sensitive and resistant to complement-mediated killing by
human serum.
4- T. cruzi invasion of eukaryotic cells is limited by the
complement system
After showing that different T. cruzi strains vary in their ability
to resist the complement system, and that some strains are
susceptible to complement killing, we decide to investigate how
efficiently the complement system can control metacyclic trypo-
mastigotes invasion of eukaryotic cells in an in vitro assay that
simulates physiological conditions.
Firstly, kinetics of invasion with CL Brener, Silvio X10/6,
Gamba 05, 860, 812 and R4 strains in Vero cells were determined
using a ratio of 5 parasites to each cell. After 30 minutes
incubation we detected invasion with all strains analysed
(Figure 4A). The highest invasion rate was detected for the strain
Cl Brener, 26 parasites per 100 cells after a 120 minute incubation,
whereas the strains Silvio X10/6, R4 and Gamba 05 had similar
rates of invasion, 12, 14 and 15 parasites per 100 cells, respectively
(Figure 4A). Lower rates were detected for the strains 860 and 812,
5 and 7 parasites per 100 cells after 120 minutes, respectively
(Figure 4A). To determine whether the complement system would
affect the parasite invasion, assays were performed by incubating
parasites with cells in the presence of 50% non-immune human
serum for 60 minutes at 37uC, and the intracellular parasites were
quantified. The amount of intracellular parasites decreased in the
presence of normal human serum when compared to invasion in
the absence of serum for the complement-sensitive strains
(Figure 4B), and a slight difference in invasion rates was detected
between them. However, the Gamba 05 strain (complement-
resistant strain) maintained similar invasion rate in the presence of
serum (Figure 4B), indicating that the decrease in cell invasion was
caused by complement-mediated lysis. Furthermore, the invasion
rates increased for all strains when the ratios of parasites per cell
were increased from 5 to 10 parasites to each cell (Figure 4B);
suggesting that the parasite load may affect the success of invasion
in the presence of serum. To certify that the complement was
limiting the parasite invasion, the assays were performed
incubating the parasites and cells for a long time period (3 hours).
The longer incubation led to an increase in cell invasion in the
absence of serum (Figure 4C); however, in the presence of serum,
the rates of invasion of the complement-sensitive strains did no
increase significantly. In contrast, the rate of invasion of the strains
Gamba 05 (complement-resistant strain) remained similar to the
rate of invasion in the absence of serum (Figure 4C). These results
indicate that the complement system limit the invasion of
complement-sensitive strains likely through the complement-
mediated lysis. Importantly, intracellular amastigotes and cell
culture-derived trypomastigotes were detected (in the supernatant)
after 72 hours of infection in the presence of serum, indicating that
parasites that succeeded in infecting the cells were able to progress
in their life cycle (not shown).
Discussion
The host innate immune system is the major barrier for
pathogens to succeed in infection, and the complement system is
one of the main arms of host defense [9]. Several molecules have
been reported to control the complement activation and killing in
T. cruzi [24,25,26,27]. However, little work has focused on the
interactions between insect-transmitted metacyclic trypomastigotes
and the complement system in non-immune serum; in addition,
whether the complement system can effectively control T. cruzi
infection.
Kinetic studies of complement activation by metacyclic
trypomastigotes have not been reported, and we decided to study
several strains from different origins to understand this mecha-
nism. Here, we show evidence that the complement system can kill
T. cruzi metacyclic trypomastigotes limiting the parasite to succeed
in invading the host cells.
Firstly, we showed that the complement activating molecules
C1q, C3, MBL, L- and H-ficolins recognize the complement-
sensitive epimastigotes. Through the deposition of C3b and C4b,
after parasite incubation with normal human serum or serum
depleted of complement factors, we showed that the lectin and
alternative pathways are the main activators of the complement
system by T. cruzi in non-immune serum. The role of the
Complement Lysis of T. cruzi
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including trypanosomatids, has been extensively explored
[17,18,35,36]. However, the lectin pathway has only recently
emerged as an important host defense mechanism due to pattern
associated recognition molecules, such as MBLs and ficolins,
which can recognize a broad range of carbohydrates on invading
pathogens [37]. Also, mutations in lectin pathway components
have been shown to increase the susceptibility to infection by
several microbes [38,39,40,41,42]. We have recently shown that
T. cruzi activate the complement lectin pathway [19], and the
current results confirm that T. cruzi strains isolated from different
hosts also activate this pathway. Other pathogens, such as
Leishmania brasiliensis, Salmonella typhimurium and Nisseria gonorrheae,
have been shown to activate the lectin pathway [43,44],
strengthening the importance of studying the mechanisms that
these pathogens evolved to inhibit this activation and complement
killing. On the other hand, as shown here and elsewhere
[17,18,19,45] the classical pathway has a limited involvement in
Figure 3. T. cruzi metacyclic trypomastigotes are killed by the complement system. A and B) Kinetics of complement-mediated killing
assays with metacyclic trypomastigotes of several T. cruzi strains. Parasites were incubated with 50% NHS at 37uC for 5 to 120 minutes and survivors
were counted. C) C3b deposition in metacyclic trypomastigotes of several T. cruzi strains. Parasites adsorbed on ELISA plates were incubated in 5%
sera treated with 10 mM EGTA and 7 mM MgCl2 for 10 and 30 minutes at 37uC, followed by anti-C3 antiserum incubation. Reactions were developed
with ABTS-peroxidase solution measured at 405 nm. D) C4b deposition in metacyclic trypomastigotes of several T. cruzi strains. Experiments were
performed as in C, except that 5% NHS anti-C4 antiserum was used. E) Live/dead viability fluorescence assay. Metacyclic trypomastigotes (812 strain)
were incubated in 50% non-immune human serum for 30 minutes at 37uC (plus NHS), or in PBS as control (buffer). After that, parasites were
incubated with 2 mM of calcein-AM and 4 mM of ethidium homodimer-1 for 30 minutes at RT, and slides were analysed by fluorescence microscopy.
Calcein-AM dye is retained by live cells and produces green fluorescence after activation by cytoplasmic esterase, whereas ethidium homodimer-1 is
excluded by the plasma membrane of live cells, enters cells with damaged membranes, and produces red fluorescence upon binding to nucleic acids
in dead cells. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0009721.g003
Figure 4. T. cruzi invasion in eukaryotic cells is limited by the complement system. A) Kinetics invasion of Vero cells by T. cruzi metacyclic
trypomastigotes. Parasites (5610
5) were incubated with Vero cells (1.0610
5, ratio 5:1, parasites:cells) for 15 to 120 minutes at 37uC, and intracellular
parasites in at least 500 cells were quantified. B) Invasion assays of Vero cells by metacyclic trypomastigotes of T. cruzi strains with or without NHS.
Parasites (5610
5 or 1.0610
6, ratios 5:1 and 10:1, parasites:cells) were incubated with Vero cells (1.0610
5) in 50% NHS for 60 minutes at 37uC. As
controls, parasites and cells (ratio 5:1) were incubated without NHS. Intracellular parasites in at least 500 cells were quantified. C) Invasion assays of
Vero cells by metacyclic trypomastigotes of T. cruzi strains with or without NHS. Parasites (5610
5, ratio 5:1, parasites:cells) were incubated with Vero
cells (1.0610
5) in 50% NHS for 3 hours at 37uC. As controls, parasites and cells (ratio 5:1) were incubated without NHS. Intracellular parasites in at least
500 cells were quantified. * p,0.05; * p,0.001.
doi:10.1371/journal.pone.0009721.g004
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suggesting that natural antibodies would have a limited capacity to
recognize T. cruzi and activate the complement system.
Assays of complement-mediated lysis, and deposition of C3b
and C4b, demonstrated that T. cruzi metacyclic trypomastigotes
activate the complement system. Furthermore, we have found that
some T. cruzi strains are highly susceptible to lysis in non-immune
serum, whereas other strains differ in their capacities to resist
complement killing. Other trypanosomatids, such as Leishmania sp.
and Chritidia sp., have been shown to be highly susceptible to
complement-mediated killing in human serum [36,46,47], indi-
cating that the complement system can act as a physiological
barrier for trypanosome infection. Since they must have evolved a
strategy to evade the complement attack; it appears that, for some
pathogens, this strategy actually uses host/vector factors. For
example, phagocytosis by macrophages and neutrophils during
this period may help them to escape the complement-mediated
killing [12,36,48]. Furthermore, it has been reported that the
saliva and intestinal content of the insect vectors contain
complement inhibitors [49], which could also help the parasites
to escape the lysis. Although complement regulators could be
contributing to complement evasion, it is possible that other
unknown evasion strategies are displayed in vivo; or perhaps the
complement sensitive strains are being transmitted by other routes
of infection, such as orally. It is important to consider that the
mechanisms employed by T. cruzi strains to escape the killing could
have evolved differently according to the hosts. Complement
system activity is different among humans, opossums, rodents and
chickens [50,51,52,53], and their effectiveness in eliminating the
parasites could be different. On the other hand, the expression and
functionality of complement regulators on T. cruzi surface may be
different in the strains, resulting in their different abilities to resist
complement killing. The expression analysis of complement
regulators in resistant and susceptible T. cruzi strains could open
the possibility to understand this difference.
We have also investigated how the complement system affects
the invasion of eukaryotic cells by T. cruzi. Experimental invasion
in vitro in the presence of non-immune human serum at nearly
physiological conditions showed that the complement system can
limit, but not avoid parasite invasion. Some strains invaded the
host cells as soon as 15 minutes, and the invasion increased
according with time. Furthermore, in the presence of human
serum the levels of invasion of the complement-sensitive strains
were dramatically decreased. However, the human serum did not
affect the complement-resistant strains to invade the cells. These
results suggest that, for the complement system to control the
infection, complete clearance during the first minutes of infection
is necessary to stop parasites from invading host cells; otherwise,
resistant strains can invade the cells and progress in their life cycle.
T. cruzi metacyclic trypomastigotes differ in their capacity to
invade the host cells. There are high and low invasive strains
[31,54], which has been related to the presence of different
parasite surface molecules [31]. It is possible that a long parasite
exposure to the complement system, before the cell invasion, can
affect the success of the infection according to the capacity of the
strain to resist the lysis.
Our data support the idea that resistance to complement-
mediated killing is not a strict characteristic of the metacyclic
trypomastigote stage of T. cruzi; rather, there are strains sensitive
and resistant to complement killing by human serum. The features
that make some strains resistant and others sensitive are still
unknown. However, the understanding that T. cruzi metacyclic
trypomastigotes can be lysed by the complement system or the
parasites could express transiently complement regulators facili-
tating them to resist the lytic effect of the complement and produce
infection; open new possibilities to investigate parasite extrinsic
mechanisms involved in immune evasion.
A detailed study of the mechanisms of complement system
activation and host cell invasion on a molecular level is essential to
understand the disease and the development of new therapies.
Drug screening initiatives have been focused mainly on parasite
metabolism targets rather than on immune evasion strategies [55].
Nevertheless, recent discoveries of complement receptors and
immune evasion strategies may reveal promising targets for
therapeutic intervention [18,19,24,26,56], which could be used
to control Chagas disease.
In summary, this study demonstrates that the human comple-
ment system can kill metacyclic trypomastigotes of T. cruzi, and the
ability to resist the complement system varies between the strains.
Indeed, the complement system acts as a physiological barrier




T. cruzi epimastigotes were cultivated in liver infusion tryptose
medium (bovine liver infusion at 5 g/l, tryptose at 5 g/l, NaCl at
4 g/l, KCl at 0.4 g/l, Na2HPO4 at 8 g/l, glucose at 2 g/l;
pH 7.2), supplemented with haemin at 10 mg/l and fetal bovine
serum 10%, at 27uC. Metacyclic trypomastigote forms were
obtained as previously described [57]. Vero cells were grown in
RPMI 1640 supplemented with 10% FBS at 37uC and 5% CO2.
Complement-mediated killing assay
Normal human serum was obtained from healthy voluntary
donors and pooled. Aliquots were stored at 280uC until use. For
complement assays, T. cruzi metacyclic trypomastigotes (5.0610
5)
in 100 ml of veronal buffer (VB, 10 mM barbital/NaCl 145 mM/
CaCl2 0.15 mM/MgCl2 0.5 mM, pH 7.4) were incubated with
100 ml of normal human serum (NHS) for 5, 10, 30, 60 and 120
minutes at 37uC. Reactions were stopped by the addition of 800 ml
of ice-cold VB. Parasite survivors were quantified in a Neubauer
chamber by light microscopy.
Depletion of MBLs and L-ficolins from NHS
Depletion of MBL and L-ficolin from human serum was
performed as previously described [19]. Firstly, to deplete NHS of
MBL, mannan-agarose (SIGMA-Aldrich) resin equilibrated in
HEPES buffer (10 mM HEPES/140 mM NaCl buffer containing
0.15 mM CaCl2 and 0.5 mM MgCl2, pH 7.4) were incubated
with NHS for 2 hour at 4uC on ice, the serum was dialysed against
2 litres of HEPES buffer. Afterwards, the same serum (MBL-
depleted) was used for L-ficolins depletion. The serum was
incubated for 2 hours on ice with N-acetyl-glucosamine-Sepharose
resins (SIGMA-Aldrich, prepared according to manufacture’s
instructions) equilibrated in 10 mM HEPES/640 mM NaCl
buffer, pH 7.4 and 5 mM ethylene diamine tetracetic acid
(EDTA). The resin was collected by centrifugation and depleted
sera (and non-treated serum) were dialyzed against 10 mM
HEPES/140 mM NaCl buffer, pH 7.4. After dialysis, MgCl2
and CaCl2 were added to final concentrations of 0.5 mM and
0.15 mM, respectively. For NHS depletion of C1q, NHS was
incubated in non-immune IgG-sepharose resin (SIGMA-Aldrich,
prepared according to manufacture’s instructions) equilibrated in
10 mM HEPES/140 mM NaCl buffer, pH 7.4 with 5 mM
EDTA and incubated for 2 hours on ice. The resin was collected
by centrifugation and depleted sera (and non-treated serum) were
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After dialysis, MgCl2 and CaCl2 were added to final concentra-
tions of 0.5 mM and 0.15 mM, respectively. Serum depletion was
confirmed by ELISA.
ELISA for complement assays
T. cruzi epimastigote or metacyclic trypomastigote forms were
fixed in 4% paraformaldehyde, and 100 ml (1.0610
6) of parasites
were incubated in each well of a 96 well ELISA MaxiSorp plate
(Nalge Nunc International) overnight at 4uC with coating buffer
(0.1M Na2CO3/0.1M NaHCO3, pH 9.5). The wells were washed
three times with phosphate buffered saline (PBS, 137 mM NaCl,
2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4), then
blocked with PBS 3% bovine serum albumin (BSA) for 2 hours at
RT. For binding of C1q, C3, L- and H-ficolins, 100 ml of 5% NHS
(diluted in VB) were added to each well, followed by a 60 minute
incubation at 37uC. For MBL binding, 20% NHS was added to
each well and incubated for 60 minutes at 37uC. Wells were
washed with PBS, then affinity purified polyclonal goat anti-MBL
antiserum (1:100) (Santa Cruz), polyclonal rabbit anti-L-ficolin
antiserum (1:500), anti-H-ficolin antiserum (1:500), anti-C1q
antiserum (1:500) and anti-C3 antiserum (1:500, diluted in PBS
3% BSA) (MRC Immunochemistry Unit, Oxford, England) were
added. After a 2 hours incubation at RT, the plate was washed as
above, and either rabbit anti-goat IgG-HRP conjugate (1:2000,
diluted in PBS 3% BSA) (Kirkegaard and Perry Laboratories) for
anti-MBL or goat anti-rabbit IgG-HRP conjugate (Bio-Rad)
(1:2000, diluted in PBS 3% BSA) for others were added and
incubated in the wells for 2 hours at RT. The wells were washed
as above, and 100 ml of ABTS peroxidase solution (Kirkegaard
and Perry Laboratories) was added. Reactions were incubated at
RT for 5 to 10 minutes and stopped with the addition of 50 mlo f
1% SDS. Absorbances (at 405 nm) were obtained through
spectrophotometric measurement. For kinetics of C3 and C4
deposition, wells previously adsorbed with parasites were incubat-
ed with either 5% NHS, or 5% MBLs/L-ficolins-depleted serum,
or 5% NHS treated with 10 mM EGTA and 7 mM MgCl2 for 5
to 60 minutes at 37uC. Afterwards, the wells were washed with
PBS, incubated with rabbit polyclonal anti-C3 antiserum (1:500)
(MRC Immunochemistry Unit) or goat polyclonal anti-C4
antibodies (1:500, diluted in PBS 3% BSA) (Calbiochem) for
2 hours at RT. After that, wells were washed, incubated with goat
anti-rabbit IgG-HRP conjugate (1:2000, diluted in PBS 3% BSA)
(Bio-Rad) and rabbit anti-goat IgG-HRP conjugate (Kirkegaard
and Perry Laboratories) (1:2000, diluted in PBS 3% BSA),
respectively and incubated for 2 hours at RT. For development,
100 ml of ABTS peroxidase solution (Kirkegaard and Perry
Laboratories) were added, incubated at RT for 5 to 10 minutes
and stopped with 50 ml of 1% SDS in H2O. Absorbances
(at 405 nm) were obtained through spectrophotometric
measurement.
Live/dead viability fluorescence assay
T. cruzi metacyclic trypomastigotes of the strain 812 (5.0610
6 in
250 ml of PBS) were incubated with 250 ml of NHS or 250 mlo f
PBS (as control) for 30 minutes at 37uC. After that, cells were
washed three times in PBS, resuspended in 1 ml of PBS containing
2 mM of calcein-AM and 4 mM of ethidium homodimer-1 (Live/
Dead Viability/Cytotoxity kit, Molecular Probes) and incubated
for 30 minutes at RT. Afterwards, cells were centrifuged for 5
minutes at 5,000 rpm, resuspended in 10 ml of PBS, and mounted
on slides with Vectashield mounting medium (Vector Laborato-
ries). For fluorescence microscopy an Olympus IX81 inverted
microscope, equipped with a U-CMAD3 camera, was used
(Olympus).
Invasion assays
Vero cells from logarithmically grown culture were treated with
trypsin, washed once with PBS and seeded on 13 mm cover slips
in 24 well plates (1.0610
5 cells per well). After 24 h, cells were
washed with serum-free RPMI 1640 and incubated with 5.0610
5
T. cruzi metacyclic trypomastigote forms for 15, 30, 60 and 120
minutes at 37uC with 5% CO2. Cells were then washed with PBS,
fixed with absolute methanol (MERCK) for 5 minutes, washed
with H2O and stained with Giemsa for 1 h at RT. Then, they
were washed with H2O and slides were mounted with aqueous
mounting medium (Biomeda). Intracellular parasites were quan-
tified by light microscopy, counting at least 500 cells per slide. For
invasion in the presence of NHS, cells were seeded as described
above and metacyclic trypomastigotes 5.0610
5 (ratio 5:1, para-
sites:cells) and 1.0610
6 (ratio 10:1, parasites:cells) were added in
the presence of 50% NHS (diluted in serum-free RPMI 1640, in a
final volume of 500 ml), followed by 60 or 180 minutes incubation
at 37uC with 5% CO2. As controls, 5.0610
5 parasites were added
to wells containing Vero cells without NHS. Staining and
quantification were performed as described above.
Data presentation and statistical analysis
All data shown are the average of two or three experiments
performed at least in triplicate. All data are shown as mean +/2
SD. Comparisons among groups were made by the unpaired t-test
for repeated measures using GraphPad Prism version 5.00 for
Windows, GraphPad Software, San Diego California USA. Values
of p,0.05 with confidence interval of 90% were considered
statistically significant unless otherwise specified.
Supporting Information
Figure S1 ELISA to analyse human serum depleted of MBL/L-
ficolins and C1q. A) 100 ml of 5% normal human serum, 5% C1q-
depleted serum and 5% MBL/L-ficolins-depleted serum were
incubated with T. cruzi epimastigotes of the strain X10/6
(previously adsorbed in ELISA plates) for 1 hour at 37uC.
Polyclonal antibodies anti-C1q was used for C1q detection.
Reactions were developed with ABTS peroxidase solution and
absorbances obtained at 405 nm. NHS (normal human serum),
MBL/L-fic-dep (MBL and L-ficolins-depleted serum), C1q-dep
(C1q-depleted serum). B) Similar to A, except that polyclonal
antibodies anti-MBL was used for detection. C) Similar to A,
except that polyclonal antibodies anti-L-ficolins was used for
detection. D) Similar to A, except that polyclonal antibodies anti-
C3 was used for detection. Significance is shown on each graph.
Data from depleted serum was compared to normal human
serum.
Found at: doi:10.1371/journal.pone.0009721.s001 (2.26 MB TIF)
Figure S2 Morphological features of T. cruzi epimastigote and
metacyclic trypomastigote stage. A) T. cruzi strain Silvio X10/6
stained with Giensa. 1 and 2, epimastigotes (3 days of culture); 3
and 4, metacyclic trypomastigotes. Metacyclic trypomastigotes
were purified by ion exchange chromatography (in DEAE-
cellulose). The efficiency of the purification was 97.5%. B)
Western blotting to detect the expression of gp82 (metacyclic
trypomastigotes stage-specific protein). Protein extract from T.
cruzi strain Silvio X10/6 (1.06107/well) epimastigotes and
metacyclic trypomastigotes were obtained with Triton-X100 1%
in PBS and separated by SDS/PAGE. The proteins were
transferred to nitrocellulose membranes and blotted with mono-
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strain Gamba 05 stained with Giensa. 1 and 2, epimastigotes (4
days of culture); 3 and 4, metacyclic trypomastigotes. Metacyclic
trypomastigotes were obtained as described in A. The efficiency of
the purification was 99%. C) Western blotting to detect the
expression of the metacyclic trypomastigotes stage-specific protein
gp82 in the strain Gamba 05. The procedure was as described in
B, except that 2.06107 parasites/well was used. E, epimastigotes;
M, metacyclic trypomastigotes.
Found at: doi:10.1371/journal.pone.0009721.s002 (5.99 MB
TIF)
Figure S3 Serum lysis of T. cruzi metacyclic trypomastigotes is
dependent on the complement system. Lysis of T. cruzi metacyclic
trypomastigotes with human serum is inhibited by serum
treatment with ethylenediamine tetraacetic acid (EDTA), protease
inhibitors or using complement consumed serum. A) Metacyclic
trypomastigotes (5.06105) of the strain Silvio X10/6 were
incubated for 1 hour at 37uC with normal human serum (NHS),
normal human serum treated with 10 mM EDTA (NHS+EDTA),
normal human serum treated with protease inhibitors (NHS+P
Inhibitors; 1 mM phenylmethylsulfonyl fluoride, 1 mM aprotinin
and 50 pM soybean trypsin inhibitor, added just before the
complement lysis assay) or complement consumed normal human
serum (NHS Consumed; consumption of complement were
obtained by incubating the serum at 37uC for 2 hours with
protein extract of 5.06106 T. cruzi epimastigotes). Parasite
survivors were quantified. B) Similar to A, but with the strain
860. Significance is shown on each graph. Data from NHS
treatment were compared to the values from NHS-EDTA, NHS-
PI and NHS Cons separately using unpaired t-test.
Found at: doi:10.1371/journal.pone.0009721.s003 (0.38 MB
TIF)
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